These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2715367)

  • 21. Drug dosing in renal insufficiency.
    Talbert RL
    J Clin Pharmacol; 1994 Feb; 34(2):99-110. PubMed ID: 8163720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Colchicine disposition in patients with familial Mediterranean fever with renal impairment.
    Ben-Chetrit E; Scherrmann JM; Zylber-Katz E; Levy M
    J Rheumatol; 1994 Apr; 21(4):710-3. PubMed ID: 8035398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency.
    Humbert G; Leroy A; Fillastre JP; Godin M
    Chemotherapy; 1979; 25(4):189-95. PubMed ID: 456077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steady-state intravenous pharmacokinetics of pirenzepine in patients with differing degrees of renal dysfunction.
    Krakamp B; Tanswell P; Vogel H; Bozler G
    Eur J Clin Pharmacol; 1989; 36(1):75-8. PubMed ID: 2917593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.
    Merdjan H; Baumelou A; Diquet B; Chick O; Singlas E
    Br J Clin Pharmacol; 1985 Feb; 19(2):211-7. PubMed ID: 3986079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition of guanadrel in subjects with normal and impaired renal function.
    Halstenson CE; Opsahl JA; Abraham PA; Schwenk MH; Andreadis NA; Antal EJ; Matzke GR
    J Clin Pharmacol; 1989 Feb; 29(2):128-32. PubMed ID: 2715368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of cibenzoline in patients with renal impairment.
    Canal M; Flouvat B; Aubert P; Guedon J; Prinseau J; Baglin A
    J Clin Pharmacol; 1985 Apr; 25(3):197-203. PubMed ID: 3998200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
    Flor S; Guay D; Opsahl J; Tack K; Matzke G
    Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of minoxidil in patients with various degrees of renal function.
    Halstenson CE; Opsahl JA; Wright CE; Fleishaker JC; Andreadis NA; Sobieraj J; Matzke GR
    J Clin Pharmacol; 1989 Sep; 29(9):798-802. PubMed ID: 2808745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of hepatic dysfunction on the pharmacokinetics of propafenone.
    Lee JT; Yee YG; Dorian P; Kates RE
    J Clin Pharmacol; 1987; 27(5):384-9. PubMed ID: 3693582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal disease and drug metabolism: an overview.
    Gibson TP
    Am J Kidney Dis; 1986 Jul; 8(1):7-17. PubMed ID: 3524205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacokinetics of habekacin in patients with chronic renal insufficiency].
    Fillastre JP; Leroy A; Humbert G; Moulin B; Bernadet P; Josse S
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):739-41. PubMed ID: 3309806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency.
    Kowalsky SF; Echols RM; Parker MA
    Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.